24Serious

Biotechnology

Ask VT AI

View News Summary

Supreme Court limits nationwide injunctions on Trump's order to restrict birthright citizenship, but its constitutionality remains unresolved.
Supreme Court upholds vital Universal Service Fund, preserving essential communication services for millions of Americans.
DHS to end Temporary Protected Status for over 500,000 Haitian nationals in 2025, despite Haiti's ongoing humanitarian crisis.

20 hours

First 100 Days

See how you scored in predicting Trump's first 100 days

Latest News

Biotechnology, CRISPR

CRISPR Therapeutics Reports Promising Phase 1 Cardiovascular Trial Results

100% left coverage1 source

Biotechnology, CRISPR

CRISPR Therapeutics Reports Promising Phase 1 Cardiovascular Trial Results

100% left coverage1 source

CRISPR Therapeutics Reports Promising Phase 1 Cardiovascular Trial Results

CRISPR Therapeutics Reports Promising Phase 1 Cardiovascular Trial Results

Stem Cell Therapy Cures 10 of 12 Severe Diabetes Patients

50% left coverage2 sources

Stem Cell Therapy Cures 10 of 12 Severe Diabetes Patients

50% left coverage2 sources

Stem Cell Therapy Cures 10 of 12 Severe Diabetes Patients

Stem Cell Therapy Cures 10 of 12 Severe Diabetes Patients

Biotechnology, CRISPR

GAMMA Investing LLC Dramatically Increases Stakes in CRISPR Therapeutics, Structure Therapeutics, REGENXBIO

100% left coverage1 source

Biotechnology, CRISPR

GAMMA Investing LLC Dramatically Increases Stakes in CRISPR Therapeutics, Structure Therapeutics, REGENXBIO

100% left coverage1 source

GAMMA Investing LLC Dramatically Increases Stakes in CRISPR Therapeutics, Structure Therapeutics, REGENXBIO

GAMMA Investing LLC Dramatically Increases Stakes in CRISPR Therapeutics, Structure Therapeutics, REGENXBIO

Biotechnology, Biotech

NKGen Expands Alzheimer’s Trial to Canada, Florida

100% left coverage1 source

Biotechnology, Biotech

NKGen Expands Alzheimer’s Trial to Canada, Florida

100% left coverage1 source

NKGen Expands Alzheimer’s Trial to Canada, Florida

NKGen Expands Alzheimer’s Trial to Canada, Florida

Harbour BioMed, Otsuka Ink $670M Deal for Autoimmune T-Cell Therapy

100% left coverage1 source

Harbour BioMed, Otsuka Ink $670M Deal for Autoimmune T-Cell Therapy

100% left coverage1 source

Harbour BioMed, Otsuka Ink $670M Deal for Autoimmune T-Cell Therapy

Harbour BioMed, Otsuka Ink $670M Deal for Autoimmune T-Cell Therapy

New CAR T Cell Therapies Advance Clinical Trials, Research, Development Globally

100% left coverage2 sources

New CAR T Cell Therapies Advance Clinical Trials, Research, Development Globally

100% left coverage2 sources

New CAR T Cell Therapies Advance Clinical Trials, Research, Development Globally

New CAR T Cell Therapies Advance Clinical Trials, Research, Development Globally

Biotechnology, Markets

J&J Dual-Targeting CAR-T Shows Up to 100% Response in Refractory Lymphoma Trial

50% center coverage3 sources

Biotechnology, Markets

J&J Dual-Targeting CAR-T Shows Up to 100% Response in Refractory Lymphoma Trial

50% center coverage3 sources

$J&J Dual-Targeting CAR-T Shows Up to 100% Response in Refractory Lymphoma Trial$

$J&J Dual-Targeting CAR-T Shows Up to 100% Response in Refractory Lymphoma Trial$

Ask VT AI

View News Summary

Supreme Court limits nationwide injunctions on Trump's order to restrict birthright citizenship, but its constitutionality remains unresolved.
Supreme Court upholds vital Universal Service Fund, preserving essential communication services for millions of Americans.
DHS to end Temporary Protected Status for over 500,000 Haitian nationals in 2025, despite Haiti's ongoing humanitarian crisis.

20 hours

First 100 Days

See how you scored in predicting Trump's first 100 days

Most Reported By
News from Biotechnology